九安醫療(002432.SZ):持續血糖監測儀(CGMS)項目正在研發當中
格隆匯7月28日丨有投資者向九安醫療(002432.SZ)提問,“4、你一直高調的糖尿病照護中心,預計到6月底,今年又比去年增加了多少家醫院?整體APP程序何時可以上線?建議公司是否可以先在美國啟用照護中心,為中國做出樣板?5、連續檢測血糖儀還要多久可以進入臨牀?你説的還要一段時間是否還要N年?6、連續血壓計臨牀結束了嗎?何時投放市場?7、你在每次回覆提問中始終複製了一條:“把具有競爭力的國內優質產品推向美國市場,準備幾年內實行?這個口號你準備喊幾年?”
九安醫療回覆稱,公司糖尿病照護相關的APP一直在正常使用,不存在您所述何時上線的情況。公司的美國子公司已通過“O+O”新模式,在慢病管理領域與五十多家診所進行合作,在醫生和患者中形成良好的口碑,帶動了更多的醫生加入。持續血糖監測儀(CGMS)項目正在研發當中。公司始終堅持糖尿病診療照護“O+O”新模式在中國、美國的落地和爆款產品兩大核心戰略,2020年的額温計、2021年的iHealth試劑盒,連續兩年的成功實踐正是對爆款產品這一戰略的集中體現,爆款產品戰略成效彰顯。相信在公司未來遇到新的挑戰時,訓練有素的團隊仍然能夠發揮凝聚力優勢。未來公司會充分利用近年來iHealth額温計、試劑盒在美國暢銷形成的品牌優勢,依據市場需求,將具有競爭力的技術和產品推向美國市場,上述業務是公司一直在做的事。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.